Latest News and Press Releases

PharmAla files audited financials for year ended August 31, 2024, completes continuance and oversubscribed private placement

PharmAla announces private placement financing

PharmAla reaches agreement in principle to trade with a clinical trial to trade its LaNeo MDMA for a data license to the trial outcomes.

PharmAla to supply Yale University with MDMA for clinical trial

PharmAla contracted to sell MDMA to Mt. Sinai Hospital, NY. Terminates Contract with CCrest Labs.

PharmAla signs contract to develop novel dosage form of LaNeo MDMA, to be used in clinical trial at University of Texas San Antonio

PharmAla Biotech signs contract to supply Harvard neuropsychiatry hospital with MDMA; Appears at CPHI Conference in Milan

PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.

PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1

PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant